Background: There are some patients with B-cell chronic lymphocytic leukemia
who exhibit an extraordinary natural resistance to this malignancy, which lasts for many years.
A snapshot of the global therapeutic scenario for B-Cell Chronic Lymphocytic Leukemia
The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia
The submission of a supplemental New Drug Application (sNDA) for labeling is based on safety and efficacy results from the Phase III HELIOS (CLL3001) trial investigating the use of IMBRUVICA (ibrutinib) plus bendamustine and rituximab (BR) versus placebo plus BR in relapsed or refractory patients with chronic lymphocytic leukemia
(CLL) or small lymphocytic lymphoma (SLL), added the company.
The report reviews key players involved in the therapeutics development for Chronic Lymphocytic Leukemia
(CLL) and enlists all their major and minor projects
14q deletions are associated with trisomy 12, NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia
and small lymphocytic lymphoma.
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
Binct JL, Auguler A, Dighlero C, et al: A new prognostic classification of chronic lymphocytic leukemia
derived from multivariate survival analysis.
Chronic lymphocytic leukemia
can result in marked immune dysfunction and immunodeficiency.
Global Markets Direct's, 'Relapsed/ Refractory Chronic Lymphocytic Leukemia
(CLL) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline.
Global Markets Direct's, 'Relapsed Chronic Lymphocytic Leukemia
(CLL) - Pipeline Review, H1 2016', provides an overview of the Relapsed Chronic Lymphocytic Leukemia
(CLL) pipeline landscape.
M2 EQUITYBITES-September 15, 2015-AbbVie submits sNDA to US FDA for IMBRUVICA for treatment-naive chronic lymphocytic leukemia
M2 PHARMA-September 15, 2015-AbbVie submits sNDA to US FDA for IMBRUVICA for treatment-naive chronic lymphocytic leukemia
USPRwire, Mon Mar 16 2015] Global Markets Direct's, 'B-Cell Chronic Lymphocytic Leukemia
- Pipeline Review, H1 2015', provides an overview of the B-Cell Chronic Lymphocytic Leukemia
's therapeutic pipeline.
Food and Drug Administration has approved Gazyva or GA101, a new monoclonal antibody, together with chlorambucil chemotherapy for the earlier untreated Chronic Lymphocytic Leukemia
, said Genentech of the Roche Group (RHHBY).